Extraordinary diseases require extraordinary solutions.
作者信息
Plotkin Stanley A, Caplan Arthur
机构信息
Pediatrics, University of Pennsylvania, PA, USA.
Bioethics, New York University, NY, USA.
出版信息
Vaccine. 2020 May 19;38(24):3987-3988. doi: 10.1016/j.vaccine.2020.04.039. Epub 2020 Apr 20.
Abstract
摘要
相似文献
1
Extraordinary diseases require extraordinary solutions.特殊的疾病需要特殊的解决方案。
Vaccine. 2020 May 19;38(24):3987-3988. doi: 10.1016/j.vaccine.2020.04.039. Epub 2020 Apr 20.
2
Search for better COVID vaccines confounded by existing rollouts.对更好的新冠疫苗的寻找因现有疫苗推广而受阻。
Nature. 2021 Jan;589(7842):340-341. doi: 10.1038/d41586-021-00015-0.
3
New challenges emerge for planned human challenge trials.针对计划性人类挑战试验出现了新的挑战。
Science. 2020 Dec 4;370(6521):1150. doi: 10.1126/science.370.6521.1150.
4
Vaccine trials ramp up in children and adolescents.针对儿童和青少年的疫苗试验正在加速推进。
Science. 2021 Feb 26;371(6532):874-875. doi: 10.1126/science.371.6532.874.
5
COVID-19 vaccination in immunocompromised patients.免疫功能低下患者的新冠病毒疫苗接种
Clin Rheumatol. 2021 Feb;40(2):797-798. doi: 10.1007/s10067-020-05547-w. Epub 2021 Jan 11.
6
Could mixing COVID vaccines boost immune response?混合接种新冠疫苗能增强免疫反应吗？
Nature. 2021 Feb;590(7846):375-376. doi: 10.1038/d41586-021-00315-5.
7
The lightning-fast quest for COVID vaccines - and what it means for other diseases.对新冠疫苗的闪电式探索及其对其他疾病的意义。
Nature. 2021 Jan;589(7840):16-18. doi: 10.1038/d41586-020-03626-1.
8
The Price of Success-How to Evaluate COVID-19 Vaccines When They're Available Outside of Clinical Trials.成功的代价——当新冠疫苗在临床试验之外可用时如何评估它们。
JAMA. 2021 Mar 9;325(10):918-921. doi: 10.1001/jama.2021.0641.
9
First vaccine may stymie hunt for better ones.首款疫苗可能会阻碍对更优疫苗的探索。
Science. 2020 Oct 23;370(6515):389-390. doi: 10.1126/science.370.6515.389.
10
How to redesign COVID vaccines so they protect against variants.如何重新设计新冠疫苗以使其能抵御变异毒株。
Nature. 2021 Feb;590(7844):15-16. doi: 10.1038/d41586-021-00241-6.
引用本文的文献
1
Controlled Human Infection Models To Accelerate Vaccine Development.控制人体感染模型以加速疫苗开发。
Clin Microbiol Rev. 2022 Sep 21;35(3):e0000821. doi: 10.1128/cmr.00008-21. Epub 2022 Jul 6.
2
Risk, benefit, and social value in Covid-19 human challenge studies: pandemic decision making in historical context.新冠病毒人体挑战研究中的风险、获益和社会价值：从历史背景看大流行决策
Monash Bioeth Rev. 2022 Dec;40(2):188-213. doi: 10.1007/s40592-022-00156-6. Epub 2022 Jun 15.
3
Pandemic vaccine testing: Combining conventional and challenge studies.大流行疫苗测试：常规研究与挑战研究相结合。
Pharmacoepidemiol Drug Saf. 2022 Jun;31(6):710-715. doi: 10.1002/pds.5429. Epub 2022 Mar 31.
4
Human Challenge Studies with Coronaviruses Old and New.人体挑战研究与新旧冠状病毒。
Curr Top Microbiol Immunol. 2024;445:69-108. doi: 10.1007/82_2021_247.
5
The vaccine against COVID-19 and institutional trust.针对 COVID-19 的疫苗和机构信任。
Enferm Infecc Microbiol Clin (Engl Ed). 2021 Dec;39(10):510-515. doi: 10.1016/j.eimce.2021.09.001. Epub 2021 Sep 10.
6
Do coronavirus vaccine challenge trials have a distinctive generalisability problem?新冠病毒疫苗挑战试验是否存在独特的可推广性问题？
J Med Ethics. 2022 Sep;48(9):586-589. doi: 10.1136/medethics-2020-107109. Epub 2021 Jun 7.
7
Human challenge trials to assess the efficacy of currently approved COVID-19 vaccines against SARS-CoV-2 variants.用于评估当前获批的新冠病毒疫苗对新冠病毒变异株有效性的人体挑战试验。
Emerg Microbes Infect. 2021 Dec;10(1):439-441. doi: 10.1080/22221751.2021.1896956.
8
Testing SARS-CoV-2 vaccine efficacy through deliberate natural viral exposure.通过故意自然病毒暴露来测试 SARS-CoV-2 疫苗的功效。
Clin Microbiol Infect. 2021 Mar;27(3):372-377. doi: 10.1016/j.cmi.2020.12.032. Epub 2021 Jan 6.
9
A cost/benefit analysis of clinical trial designs for COVID-19 vaccine candidates.COVID-19 疫苗候选者临床试验设计的成本效益分析。
PLoS One. 2020 Dec 23;15(12):e0244418. doi: 10.1371/journal.pone.0244418. eCollection 2020.
10
Key criteria for the ethical acceptability of COVID-19 human challenge studies: Report of a WHO Working Group.COVID-19 人体挑战研究的伦理可接受性的关键标准：世卫组织工作组的报告。
Vaccine. 2021 Jan 22;39(4):633-640. doi: 10.1016/j.vaccine.2020.10.075. Epub 2020 Oct 28.
本文引用的文献
1
Estimates of the severity of coronavirus disease 2019: a model-based analysis.新型冠状病毒疾病 2019 严重程度的估计：基于模型的分析。
Lancet Infect Dis. 2020 Jun;20(6):669-677. doi: 10.1016/S1473-3099(20)30243-7. Epub 2020 Mar 30.
2
The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment.新型冠状病毒（SARS-CoV-2）爆发的前 75 天：最新进展、预防和治疗。
Int J Environ Res Public Health. 2020 Mar 30;17(7):2323. doi: 10.3390/ijerph17072323.
3
Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure.人类挑战研究加速冠状病毒疫苗许可。
J Infect Dis. 2020 May 11;221(11):1752-1756. doi: 10.1093/infdis/jiaa152.
4
The 1918 Influenza Pandemic and Its Legacy.1918 年流感大流行及其影响
Cold Spring Harb Perspect Med. 2020 Oct 1;10(10):a038695. doi: 10.1101/cshperspect.a038695.
5
The Future of Flu: A Review of the Human Challenge Model and Systems Biology for Advancement of Influenza Vaccinology.流感的未来：人类挑战模型和系统生物学在流感疫苗学中的应用综述。
Front Cell Infect Microbiol. 2019 Apr 17;9:107. doi: 10.3389/fcimb.2019.00107. eCollection 2019.
6
The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics.人类病毒挑战模型：加速呼吸道抗病毒药物、疫苗和新型诊断方法的评估。
Respir Res. 2018 Jun 22;19(1):123. doi: 10.1186/s12931-018-0784-1.
7
The complexity and cost of vaccine manufacturing - An overview.疫苗生产的复杂性与成本——概述
Vaccine. 2017 Jul 24;35(33):4064-4071. doi: 10.1016/j.vaccine.2017.06.003. Epub 2017 Jun 21.
8
Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!).一种重组水疱性口炎病毒载体疫苗预防埃博拉病毒病的有效性和效果：几内亚环状疫苗接种、开放标签、整群随机试验（埃博拉到此为止！）的最终结果
Lancet. 2017 Feb 4;389(10068):505-518. doi: 10.1016/S0140-6736(16)32621-6. Epub 2016 Dec 23.
Zotero 插件